Researchers at Roswell Park Comprehensive Cancer Center have identified a new vulnerability in lung adenocarcinoma, the most prevalent form of non-small cell lung cancer. Their study reveals that the protein agrin, typically involved in maintaining tissue structure, is overproduced in tumors with mutations in the EGFR gene. This excess agrin enhances EGFR signaling, promoting tumor growth and resistance to treatment. By targeting agrin, scientists aim to disrupt this process, potentially improving the effectiveness of existing EGFR-focused therapies and reducing the likelihood of cancer recurrence .
The research team tested a combination treatment that pairs standard EGFR inhibitors with methods to suppress agrin. In laboratory and animal models, this approach significantly slowed tumor progression compared to EGFR therapy alone. Additionally, the study suggests that measuring agrin levels through a simple blood test could help monitor treatment response and predict relapse risk. These findings will be presented at the upcoming 2025 American Association for Cancer Research Annual Meeting, highlighting a promising avenue for more personalized and effective lung cancer treatments. Click for More Details
